Cargando…

Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis

BACKGROUND: Geniposidic acid (GPA), one of the active components of Eucommia ulmoides, promote bone formation and treat osteoporosis by activating farnesoid X receptor (FXR). However, GPA has low oral availability and lack of bone targeting in the treatment of bone related diseases. With the develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meijing, Zhu, Danqi, Jin, Fujun, Li, Shuang, Liu, Xiangning, Wang, Xiaogang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Speaking Orthopaedic Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579733/
https://www.ncbi.nlm.nih.gov/pubmed/36313979
http://dx.doi.org/10.1016/j.jot.2022.07.007
_version_ 1784812247676092416
author Liu, Meijing
Zhu, Danqi
Jin, Fujun
Li, Shuang
Liu, Xiangning
Wang, Xiaogang
author_facet Liu, Meijing
Zhu, Danqi
Jin, Fujun
Li, Shuang
Liu, Xiangning
Wang, Xiaogang
author_sort Liu, Meijing
collection PubMed
description BACKGROUND: Geniposidic acid (GPA), one of the active components of Eucommia ulmoides, promote bone formation and treat osteoporosis by activating farnesoid X receptor (FXR). However, GPA has low oral availability and lack of bone targeting in the treatment of bone related diseases. With the development of modern technology, small molecules, amino acids, or aptamers are used for biological modification of drugs and target cells in bone tissue, which has become the trend of bone targeted research. METHODS: In this study, SDSSD (an osteoblast-targeting peptide) were modified in GPA using Fmoc solid-phase synthesis technique to form a new SDSSD-GPA conjugate (SGPA). The bone targeting of SGPA was evaluated using in vivo imaging and cell co-culture. In vitro, the effect of SGPA on cytotoxicity, osteoblastic activity, and mineralization ability were studied in mouse primary osteoblasts (OBs). In vivo, the therapeutic effect of SGPA on osteoporosis using an ovariectomized (OVX) mouse model. The bone mass, histomorphometry, serum biochemical parameters, and the molecular mechanism were evaluated. RESULTS: SGPA was enriched in OBs and tends to accumulate in bone tissue. In vitro, SGPA significantly enhanced the osteogenic activity and mineralization of OBs compared with GPA. In vivo, SGPA enhanced serum BALP and P1NP levels, increased the trabecular bone mass of the mice, and SGPA administration have a higher bone mineralization deposition rate than the GPA-treated mice. Moreover, SGPA significantly activated FXR and Runt-related transcription factor 2 (RUNX2). CONCLUSIONS: Collectively, SGPA is enriched into OBs, and promotes bone formation by activating FXR-RUNX2 signalling, effectively treating osteoporosis at relatively low doses. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: This study demonstrates a more efficient and safe application of GPA in treating osteoporosis, provide a new concept for the bone targeted application of natural compounds.
format Online
Article
Text
id pubmed-9579733
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Chinese Speaking Orthopaedic Society
record_format MEDLINE/PubMed
spelling pubmed-95797332022-10-27 Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis Liu, Meijing Zhu, Danqi Jin, Fujun Li, Shuang Liu, Xiangning Wang, Xiaogang J Orthop Translat Original Article BACKGROUND: Geniposidic acid (GPA), one of the active components of Eucommia ulmoides, promote bone formation and treat osteoporosis by activating farnesoid X receptor (FXR). However, GPA has low oral availability and lack of bone targeting in the treatment of bone related diseases. With the development of modern technology, small molecules, amino acids, or aptamers are used for biological modification of drugs and target cells in bone tissue, which has become the trend of bone targeted research. METHODS: In this study, SDSSD (an osteoblast-targeting peptide) were modified in GPA using Fmoc solid-phase synthesis technique to form a new SDSSD-GPA conjugate (SGPA). The bone targeting of SGPA was evaluated using in vivo imaging and cell co-culture. In vitro, the effect of SGPA on cytotoxicity, osteoblastic activity, and mineralization ability were studied in mouse primary osteoblasts (OBs). In vivo, the therapeutic effect of SGPA on osteoporosis using an ovariectomized (OVX) mouse model. The bone mass, histomorphometry, serum biochemical parameters, and the molecular mechanism were evaluated. RESULTS: SGPA was enriched in OBs and tends to accumulate in bone tissue. In vitro, SGPA significantly enhanced the osteogenic activity and mineralization of OBs compared with GPA. In vivo, SGPA enhanced serum BALP and P1NP levels, increased the trabecular bone mass of the mice, and SGPA administration have a higher bone mineralization deposition rate than the GPA-treated mice. Moreover, SGPA significantly activated FXR and Runt-related transcription factor 2 (RUNX2). CONCLUSIONS: Collectively, SGPA is enriched into OBs, and promotes bone formation by activating FXR-RUNX2 signalling, effectively treating osteoporosis at relatively low doses. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: This study demonstrates a more efficient and safe application of GPA in treating osteoporosis, provide a new concept for the bone targeted application of natural compounds. Chinese Speaking Orthopaedic Society 2022-10-17 /pmc/articles/PMC9579733/ /pubmed/36313979 http://dx.doi.org/10.1016/j.jot.2022.07.007 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Liu, Meijing
Zhu, Danqi
Jin, Fujun
Li, Shuang
Liu, Xiangning
Wang, Xiaogang
Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
title Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
title_full Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
title_fullStr Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
title_full_unstemmed Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
title_short Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
title_sort peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579733/
https://www.ncbi.nlm.nih.gov/pubmed/36313979
http://dx.doi.org/10.1016/j.jot.2022.07.007
work_keys_str_mv AT liumeijing peptidemodifiedgeniposidicacidtargetsboneandeffectivelypromotesosteogenesis
AT zhudanqi peptidemodifiedgeniposidicacidtargetsboneandeffectivelypromotesosteogenesis
AT jinfujun peptidemodifiedgeniposidicacidtargetsboneandeffectivelypromotesosteogenesis
AT lishuang peptidemodifiedgeniposidicacidtargetsboneandeffectivelypromotesosteogenesis
AT liuxiangning peptidemodifiedgeniposidicacidtargetsboneandeffectivelypromotesosteogenesis
AT wangxiaogang peptidemodifiedgeniposidicacidtargetsboneandeffectivelypromotesosteogenesis